Source link : https://www.newshealth.biz/health-news/as-glp-1-demand-goes-up-access-and-coverage-go-down/
ORLANDO, Fla — Experts debating the pressing issue of how to prioritize patients in the increasingly common scenario of loss of access or insurance coverage for anti-obesity glucagon-like peptide 1 (GLP-1) receptor agonist drugs argued that comorbidities and obesity severity should strongly warrant continued coverage — while offering key strategies for getting and retaining approval […]
Author : News Health
Publish date : 2024-07-18 13:26:08
Copyright for syndicated content belongs to the linked Source.
Categories